GamaMabs Pharma SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GamaMabs Pharma SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11305
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GamaMabs Pharma SA (GamaMabs) is a clinical-stage immuno-oncology company that develops optimized therapeutic antibodies for the treatment of cancer. The company’s lead product candidate GM102, is an anti-AMHR2, Emabling engineered humanized mAb product targeting the receptor of anti-Mullerian hormone (AMH) in gynecological cancers. It develops its products through EMABling, HuMabFc platforms, and others. GamaMabs’s products find therapeutic applications in the areas of ovarian and endometrium cancer among others. The company works in partnership with academic partners and other research centers such as Institut Gustave Roussy, Institut Curie, Institut Cochin, Institut de Recherche en Cancerologie de Montpellier and Mass General Hospital Boston. GamaMabs is headquartered at Toulouse, France.

GamaMabs Pharma SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GamaMabs Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
GamaMabs Pharma Raises USD16 Million in Series B Financing 10
GamaMabs Pharma Raises USD0.7 Million in Venture Financing 11
GamaMabs Pharma Raises USD5 Million in Series A Financing 12
GamaMabs Pharma Raises US$4.2 Million In Seed Financing 13
Partnerships 14
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 14
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 15
Licensing Agreements 16
GamaMabs Enters into Licensing Agreement with MedImmune 16
GamaMabs Pharma SA – Key Competitors 17
GamaMabs Pharma SA – Key Employees 18
GamaMabs Pharma SA – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Key Facts 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GamaMabs Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GamaMabs Pharma SA, Deals By Therapy Area, 2012 to YTD 2018 8
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GamaMabs Pharma Raises USD16 Million in Series B Financing 10
GamaMabs Pharma Raises USD0.7 Million in Venture Financing 11
GamaMabs Pharma Raises USD5 Million in Series A Financing 12
GamaMabs Pharma Raises US$4.2 Million In Seed Financing 13
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 14
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 15
GamaMabs Enters into Licensing Agreement with MedImmune 16
GamaMabs Pharma SA, Key Competitors 17
GamaMabs Pharma SA, Key Employees 18

List of Figures
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[GamaMabs Pharma SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Double Bond Pharmaceutical International AB (DBPB):製薬・医療:M&Aディール及び事業提携情報
    Summary Double Bond Pharmaceutical International AB (DBP) is a pharmaceutical company that design, develop and commercialize therapies for cancer and autoimmune diseases. The company’s product pipeline includes SI-053 (Temodex), a novel therapy to treat malignant brain tumors; SA-033, SA-042, and SA …
  • Curetis NV (CURE):企業の製品パイプライン分析2018
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Sumitomo Heavy Industries Ltd (6302)
    Sumitomo Heavy Industries Ltd (6302) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Bangkok Bank Public Co Ltd:企業の戦略・SWOT・財務情報
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Windtree Therapeutics Inc (WINT)-医療機器分野:企業M&A・提携分析
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • Syntimmune Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Syntimmune Inc (Syntimmune) is a clinical-stage biotechnology company that focuses to develop Fc receptor (FcRn) based antibody therapeutics for the treatment of autoimmune diseases. Its lead pipeline products includes SYNT001, an investigational humanized IgG4 monoclonal antibody that inhib …
  • Landry’s Inc:企業の戦略・SWOT・財務情報
    Landry's Inc - Strategy, SWOT and Corporate Finance Report Summary Landry's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • TRACOE medical GmbH:企業の戦略的SWOT分析
    TRACOE medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Whiting Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Whiting Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Whiting Petroleum Corp (Whiting Petroleum) is an independent oil and gas company that develops, produces, acquires and explores crude oil, natural gas and natural gas liquids (NGL) in the Rock …
  • Abercrombie & Fitch Co:企業の戦略・SWOT・財務分析
    Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report Summary Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • RadiSys Corp (RSYS):企業の財務・戦略的SWOT分析
    Summary RadiSys Corp (RadiSys) is a provider of communication services. The company offers products include mobility engine, mediaengine, dcengine and embedded Products. It offers contact support, serviceengine, conceptualization, software customization, network design and integration; testing and a …
  • 23andMe Inc:医療機器:M&Aディール及び事業提携情報
    Summary 23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. Its service portfolio includes clinical development, research and development, ancestry service …
  • Shell Pakistan Ltd (SHEL):企業の財務・戦略的SWOT分析
    Summary Shell Pakistan Ltd (Shell Pakistan), a subsidiary of Royal Dutch Shell plc is an oil and gas company that markets petroleum products and compressed natural gas. The company operates through three segments such as retail, lubricants and aviation. It retail segment offers a range of fuels such …
  • Hospira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Hospira Inc (Hospira), a subsidiary of Pfizer Inc, is a medical device company that offers injectable drugs and infusion technologies. The company offers products such as generic acute-care and oncology injectables, biosimilars, infusion systems, IV sets, IV safety devices, biosimilars, diff …
  • Gentera SAB de CV (GENTERA):企業の財務・戦略的SWOT分析
    Gentera SAB de CV (GENTERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Indigo Books & Music Inc:企業の戦略・SWOT・財務分析
    Indigo Books & Music Inc - Strategy, SWOT and Corporate Finance Report Summary Indigo Books & Music Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Alector LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Alector LLC (Alector) is a biotechnology company that develops therapies for immune system to cure neurodegeneration and cancer. The company discovers and develops immune modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. It combines state-of-the-art antibody …
  • Cantex Mine Development Corp (CD):企業の財務・戦略的SWOT分析
    Summary Cantex Mine Development Corp (Cantex) is a mining and mineral exploration company. The company’s business activities include acquisition, exploration, and development of cobalt, copper, manganese, zinc, gold, nickel, and platinum properties. Its projects comprise Al Hariqah Gold project, Al …
  • Grendene S.A. (GRND3):企業の財務・戦略的SWOT分析
    Grendene S.A. (GRND3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Virgin Active Limited
    Virgin Active Limited - Strategy, SWOT and Corporate Finance Report Summary Virgin Active Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆